# Marijuana’s menace: cannabis use disorder spiking, study says > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/marijuanas-menace-cannabis-use-disorder-spiking-study-says/ > **Published:** 2026-08-20T17:17:51-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:16:03-04:00 > **Clinical Summary:** Clinical commentary on rising cannabis use disorder prevalence. Evidence-based screening, diagnostic criteria, and practice implications for clinicians. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchMental HealthSafetyPolicyTHCNeurologyAnxiety Why This Matters Clinicians need to understand that [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) diagnoses are increasing, which means they should routinely screen patients for problematic use patterns and be prepared to counsel on dependence risk, particularly as cannabis products become more potent and accessible. This trend has direct implications for mental health, [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) treatment capacity, and the need for evidence-based interventions, since many patients may not recognize cannabis as addictive or seek help without clinical identification of disorder. Clinical Summary This [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) report highlights rising prevalence of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder (CUD) among the U.S. population, indicating that increased cannabis availability and normalized social attitudes have outpaced clinical recognition of addiction potential. The spike in CUD diagnoses reflects a significant gap between public perception of cannabis as a low-risk substance and the clinical reality that regular use, particularly with higher potency products now available, carries meaningful risks for psychological dependence and functional impairment. For clinicians, this trend underscores the importance of routine screening for [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) patterns and CUD symptoms during patient evaluations, especially given that many patients may not spontaneously disclose use or recognize problematic consumption themselves. The rising incidence also suggests growing demand for evidence-based treatment approaches and highlights the need for physician education about CUD assessment and management strategies. Clinicians should incorporate standardized screening tools for [cannabis dependence](https://cedclinic.com/ptsd-cannabis-dependence-veterans-social-support/) into standard practice and be prepared to counsel patients about dose-dependent risks and the potential for addiction with modern high-potency cannabis products. Dr. Caplan’s Take “We’re seeing legitimate population-level data showing increased [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) diagnoses, particularly in certain demographics, and that’s a clinical signal we need to take seriously. The challenge is parsing out whether this reflects true increases in problematic use patterns or changing diagnostic practices and help-seeking behavior, but either way it underscores that cannabis isn’t risk-free and some users do develop genuine dependence that warrants evidence-based treatment.” Clinical Perspective 💊 Rising rates of [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) documented in recent epidemiological studies reflect a meaningful clinical concern that clinicians should incorporate into routine [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) screening. However, it is important to contextualize these findings within broader patterns of changing cannabis potency, availability of high-risk consumption methods (such as concentrates), and demographic shifts in who uses cannabis, which complicate simple interpretation of disorder prevalence trends. Simultaneously, clinicians should recognize that [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder diagnostic criteria capture a spectrum of problematic use, and not all individuals who use cannabis regularly will meet clinical thresholds for disorder or experience functional impairment. When evaluating patients who report cannabis use, a structured assessment of frequency, route of administration, motivations for use, and impact on work, relationships, and mental health will help differentiate between casual use and clinically significant disorder that warrants intervention or referral to specialty [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) services. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Marijuana%27s%20menace%3A%20cannabis%20use%20disorder%20spiking%2C%20study%20says%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D74436)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D74436)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Marijuana%27s%20menace%3A%20cannabis%20use%20disorder%20spiking%2C%20study%20says%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D74436)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://x.com/thephillyvoice/status/2090481541784731957](https://x.com/thephillyvoice/status/2090481541784731957) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).